Status:
RECRUITING
A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Breast Neoplasms
Eligibility:
All Genders
18-100 years
Detailed Description
This non-interventional study aims to provide information on real-world effectiveness, safety and tolerability, management of adverse events, QoL and patient compliance of patients with HR+/HER2- earl...
Eligibility Criteria
No eligibility criteria provided.
Key Trial Info
Start Date :
February 20 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2030
Estimated Enrollment :
3250 Patients enrolled
Trial Details
Trial ID
NCT06830720
Start Date
February 20 2025
End Date
June 30 2030
Last Update
March 3 2026
Active Locations (267)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Innsbruck, Tyrol, Austria, 6020
2
Novartis Investigative Site
Linz, Upper Austria, Austria, 4010
3
Novartis Investigative Site
Graz, Austria, 8036
4
Novartis Investigative Site
Klagenfurt, Austria, 9020